QED

QED Achondroplasia Clinical Update

FEATURED

QED Therapeutics, Inc. (“QED”), a subsidiary of BridgeBio Pharma, Inc. (“BridgeBio”) focuses on bringing medicine to people living with conditions that are caused by changes in fibroblast growth factor receptor (FGFR) genes. QED is developing a medicine which may improve the overall health and quality of life of people with